Opinion|Videos|December 23, 2024
The Role of Molecular Testing in Treatment Decisions for NSCLC
This video segment explores the critical role of biomarker testing in identifying patients with ALK-positive NSCLC, discussing the clinical characteristics that guide the use of ALK inhibitors and addressing challenges in implementing comprehensive molecular testing in community settings.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What characteristics make this patient particularly suitable for treatment with an ALK inhibitor?
- How important is biomarker testing in informing treatment decisions?
- What is your approach to testing and what barriers are there for testing in the community?
Advertisement
Related to this article
Pembrolizumab plus SBRT produced more toxicity vs SBRT alone among patients with early-stage non–small cell lung cancer in the phase 3 KEYNOTE-867 trial.
An end-of-phase 2 meeting with the FDA supports a phase 3 development program for silevertinib in patients with locally advanced or metastatic NSCLC.
The FDA issued a Not Approvable Letter due to uncertainty around the degree of clinical benefit with Optune Mya for patients with NSCLC and brain metastases.
In pooled phase 1/2 data, the PD-1/VEGF bispecific antibody cesalatamig produced a 33% objective response rate in PD-(L)1–resistant/refractory NSCLC.
Findings may provide reassurance to patients with early-stage disease that surgery may help improve survival rates.
Advertisement
Advertisement
Trending on CancerNetwork
1
Anthracycline Chemo May Accelerate Biological Aging in Breast Cancer Survivors
2
Contextualizing MRD Negativity and PFS Across Treatment Regimens in Relapsed/Refractory Multiple Myeloma
3
CELMoDs With CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
4
What Sustained MRD Negativity Can Settle About Stopping Myeloma Maintenance
5